(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054236 A1

(51) International Patent Classification[7]: C07D 471/04, 519/00, C07K 5/00, C07H 21/00, A61P 35/00, A61K 31/4745

(21) International Application Number:
PCT/EP2004/013106

(22) International Filing Date:
18 November 2004 (18.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P200302821 20 November 2003 (20.11.2003) ES

(71) Applicants *(for all designated States except US)*: **CRYSTAX PHARMACEUTICALS S.L.** [ES/ES]; Josep Samitier 1-5, E-08028 Barcelona (ES). **CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS** [ES/ES]; Serrano, 113, 28006 Madrid (ES). **UNIVERSITAT POLITÈCNICA DE CATALUNYA** [ES/ES]; Jordi Girona, 31, E-8034 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AYMAMI BOFARULL, Juan** [ES/ES]; Universitat Politècnica de Catalunya, Jordi Girona, 31, E-08034 Barcelona (ES). **COLL CAPELLA, Miquel** [ES/ES]; Consejo Superior de Investigaciones Cientificas, Serrano, 113, E-28006 Madrid (ES). **LLEBARIA SOLDEVILA, Amadeo** [ES/ES]; Consejo Superior de Investigaciones Cientificas, Serrano, 113, E-28006 Madrid (ES). **NAVARRO MUÑOZ, Isabel** [ES/ES]; Crystax Pharmaceuticals, S.L., Parc Cientific de Barcelona, Josep Samitier 1-5, E-08028 Barcelona (ES).

(74) Common Representative: **CRYSTAX PHARMACEUTICALS S.L.**; JUNGHANS, Claas, Josep Samitier 1-5, E-08028 Barcelona (ES).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designation US*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER





(57) Abstract: Compounds of formula G_1-L-G_2, where -G_1 is a radical structurally close to cryptolepine, -L- is a single covalent bond or a covalent linking biradical selected from $(CH_2)_r$NR'''$(CH_2)_s$ and -$(CH_2)_r$NR'''$(CH_2)_s$NR''''$(CH_2)_t$-, -R''' and -R'''' are radicals, same or different, selected from the group consisting of H and (C_1-C_3)-alkyl; r, s and t are an integer from 1 to 3 and, -G_2 is H or a radical structurally close to -G_1, are intercalators. They are compounds which intercalate between DNA base pairs, and are useful as therapeutic agents against cancer, as assess by an in vitro test of cytotoxicity with human leukemia cells Jurkat E6-1 and human carcinoma cells GLC-4. Preferred compounds are those where -G_1 is bonded to -L- through a carbonyl amino and -L-is -$(CH_2)_3NCH_3(CH_2)_3$ or -$(CH_2)_2NCH_3(CH_2)_sNCH_3(CH_2)_2$- where s = 2 or 3. -$G_1$ is a radical selected from (IIa) y (IIb); -G_2 is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

WO 2005/054236 A1